As a result, prescriptions of GLP-1 diabetes and weight-loss medications more than doubled between 2022 and 2023
Lead author, Luis-Emilio Garca-Prez, MD, PhD, MBA, explained the key findings to Medical News Today : This was a post-hoc sub-group data analysis of the SURMOUNT-1, SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 phase 3 trials that showed tirzepatide injections (5 mg, 10 mg, 15 mg) significantly reduced body weight compared to placebo regardless of sex, with greater body weight reduction associated with tirzepatide in females compared to males. Luis-Emilio Garca-Prez, MD While the SM-1 and SM-2 trials involved randomization immediately after a screening period, SM-3 had a 12-week lead-in phase with intensive lifestyle changes, and SM-4 had a 36-week lead-in with open-label tripeptide treatment
If you are losing weight steadily at 1.0 mg with tolerable side effects, staying there is a perfectly valid strategy
As evident, both tirzepatide and retatrutide can induce significant weight loss within the range of 24-25% from baseline after 48-88 weeks of therapy
Overall Rating: NewSelf 3.8/5 | MEDVi 2.8/5 Quick Verdict: NewSelf wins on price and regulatory standing, with no FDA warning letter and no BBB failing grade
That was originally developed as an asthma drug
